AI-Powered Adverse Drug Reaction Analysis System
Every approved drug carries known and hidden adverse effects. Manually processing 30 million reports from FAERS or EudraVigilance is a task that can take a safety officer weeks. We built an AI system that prioritizes signals in one hour, reducing detection time by 40% and saving up to 2 million rubles annually on manual analysis. The system integrates with FAERS (over 30 million reports), EudraVigilance, VigiBase, as well as electronic health records (EHRs) and social networks. NLP modules based on BioBERT and ClinicalBERT extract mentions of adverse reactions from texts. This article covers the architecture of such a system—from data sources to regulatory reports.
Our experience: more than 10 pharmacovigilance projects for European and Russian regulators. The adverse drug reaction analysis system combines statistical methods, NLP, and graph neural networks.
Why classical disproportionality analysis is outdated
PRR and ROR generate up to 90% false signals. Bayesian BCPNN (WHO) is more robust but requires strong priors. We combine frequentist and Bayesian approaches, then rank signals with an ML model trained on historically confirmed cases. Precision improves threefold.
What data sources do we use
| Category | Examples | Volume |
|---|---|---|
| Regulatory databases | FAERS, EudraVigilance, VigiBase | 130M+ reports |
| Real World Data | EHRs, insurance claims, registries | Trillions of records |
| Patient-generated | Twitter, Reddit, health forums | Petabytes of text |
| Literature | PubMed, ClinicalTrials.gov | 30M+ articles |
Real World Data is key to rare ADRs. In the UK Biobank EHR, we identified a signal for statins that had not passed through FAERS for years.
Methods of adverse drug reaction analysis: from statistics to GNN
Frequentist disproportionality
Classics: PRR, ROR, chi-squared. Automatic monitoring of FAERS on a weekly basis. Downside: 90% false positives.
Bayesian signal detection
BCPNN (WHO), GPS (Empirical Bayes). EBGM > 2 and ≥3 cases → signal. According to our tests, this is 20% more accurate than frequentist methods.
ML on EHR/claims
Self-controlled case series eliminate confounding by indication. Propensity score matching on millions of patients. Example: drug A vs B—how often do cardiovascular complications occur?
Text mining from literature
Co-occurrence analysis: drug and ADR in the same article. NLP (BioBERT) extracts cause-effect pairs. Signals from literature precede FAERS by 6–12 months.
Network pharmacology
Details on the GNN approach
Graph: drug → proteins → processes → phenotypes. A GNN predicts ADRs through shared targets. Example: drug A binds to protein T, which is also targeted by drug B (known cardiotoxicity) → potential cardiotoxicity of A.
| Method | Precision | Recall | Note |
|---|---|---|---|
| PRR/ROR | 10% | 70% | Fast filter |
| BCPNN | 30% | 85% | WHO recommendation |
| GNN (our model) | 65% | 90% | 85% top-3 recall on DDI |
Methods for detecting drug-drug interactions
DDI prediction methods include modeling CYP450 and pharmacodynamic effects. ML approaches: matrix factorization, GNN on similarity graphs, knowledge graph embeddings (TransE, RotatE). We train on TWOSIDES (65k pairs) and validate on DrugBank. Our GNN approach achieves 85% top-3 recall—1.5 times better than classical factorization.
Postmarketing monitoring via EHR: analysis of patients on drug combinations versus a control group.
How we implement the system: step-by-step process
- Data analysis—assessment of available sources (FAERS, EHR, social) and their quality.
- Pipeline design—ETL, de-identification, NLP (BioBERT/ClinicalBERT), ML.
- Integration with sources—via APIs with FAERS, EudraVigilance, EHR.
- ML module development—fine-tuning BioBERT, GNN for DDI, Bayesian detector.
- Testing and validation—on historical signals, comparison with manual assessment.
- Deployment—containerization (Docker, Kubernetes), drift monitoring.
- Team training—workshops for safety officers, documentation.
Result: a platform your team uses daily. The average annual saving for a pharmaceutical company after implementation is 3 to 5 million rubles.
What the work includes
When you order development of an AI system for pharmacovigilance, you get:
- Audit of current processes and data (FAERS, EHR, claims).
- Architecture design with model selection (NLP, GNN, Bayesian).
- Integration with regulatory sources (FAERS API, EudraVigilance).
- Development and fine-tuning of models (BioBERT, ClinicalBERT, GNN).
- Deployment in containers (Docker, Kubernetes) with monitoring.
- Documentation and team training (safety officers, analysts).
- Post-launch support (model updates, dashboards).
Interpretability for the regulator
All signals undergo medical validation. Output:
- Ranked list with an evidence base.
- Excerpts from FAERS and literature (VigiBase, WHO-ART).
- Draft assessment for the Medical Safety Officer.
AI is a prioritization tool, not a replacement for experts. Without it, 80% of signals are lost in the noise. The Journal of Biomedical Informatics notes that using ML reduces analysis time by 60%.
Development time for a basic platform is 8–12 weeks. A full solution with EHR, claims, and GNN can take up to 6 months. We guarantee integration with your existing infrastructure. Consult our engineers for a project estimate within two days. Order a pilot project to test the system on your data.
Contact us to assess your project in two days.